Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SS109 Phase 1b/2 in Hemophilia with Inhibitors
NCT06010953Phase 2Completed
- Sponsor
- Gensciences
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human coagulation factor VIIa Fc fusion protein in hemophilia A, hemophilia B (HB), sponsored by Gensciences. Started Oct 2023; status: completed.
02
Drugs
recombinant human coagulation factor VIIa Fc fusion protein
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT06010953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010953.